



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Andreas MENRAD et al.

Examiner: Maher M. HADDAD

Serial No.: 10/676,049

Group Art Unit: 1644

Filed: October 2, 2003

Title: RECEPTOR OF THE ED β -FIBRONECTIN DOMAINS

RESPONSE TO RESTRICTION REQUIREMENT

Mail Stop
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Responsive to the office action of June 30, 2004, applicants hereby elect Group I for screening antibodies and also elect sequence ID No. 4. This election is made with traverse.


Firstly, the examiner has demonstrated in the office action that absolutely no burden would be required in examining all claims. All fall into precisely the same subclasses.

Furthermore, the linking claims relate to screening of compounds in general, which is the norm for such screening claims. The mere fact that various kinds of compounds can be screened and are the subject of various claims cannot possibly sensibly require a restriction.

Furthermore, the requirements of 37 CFR §1.141 as stated by the examiner on page 3 of the office action are fully operable here. This is, all of the depending claims will reflect a reasonable number of species, under the linking independent claim and will needed to be added back into the application anyway.

The Commissioner is hereby authorized to charge any fees associated with this response or credit any overpayment to Deposit Account No. 13-3402.

Respectfully submitted,



Anthony J. Zelano, Reg. No. 27,969
Attorney for Applicants

MILLEN, WHITE, ZELANO
& BRANIGAN, P.C.
Arlington Courthouse Plaza 1, Suite 1400
2200 Clarendon Boulevard
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410

Attorney Docket No.: SCH-1832-D01

Date: September 7, 2004
AJZ:bef K:\Sch\1832D1\RespDue9.30.doc